Digestive Diseases and Sciences

, Volume 53, Issue 9, pp 2556–2563

Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres

  • T. F. Jakobs
  • S. Saleem
  • B. Atassi
  • E. Reda
  • R. J. Lewandowski
  • V. Yaghmai
  • F. Miller
  • R. K. Ryu
  • S. Ibrahim
  • K. T. Sato
  • L. M. Kulik
  • M. F. Mulcahy
  • R. Omary
  • R. Murthy
  • M. F. Reiser
  • R. Salem
Original Paper


Purpose To identify changes in hepatic parenchymal volume, fibrosis, and induction of portal hypertension following radioembolization with glass microspheres for patients with metastatic disease to the liver. Results In our series of sequential bilobar (n = 17) treatments, a mean decrease in liver volume of 11.8% was noted. In this group, a mean splenic volume increase of 27.9% and portal vein diameter increase of 4.8% were noted. For patients receiving unilobar treatments (n = 15), mean ipsilateral lobar volume decrease of 8.9%, contralateral lobar hypertrophy of 21.2%, and a 5.4% increase in portal vein diameter were also noted. These findings were not associated with clinical toxicities. Conclusion90Yttrium radioembolization utilizing glass microspheres in patients with liver metastases results in changes of hepatic parenchymal volume and also induced findings suggestive of fibrosis and portal hypertension. Further studies assessing the long-term effects are warranted.


Liver metastases Radioembolization Radiation-induced liver disease Palliative treatment Fibrosis Portal hypertension 


  1. 1.
    Macdonald JS (1999) Adjuvant therapy of colon cancer. CA Cancer J Clin 49(4):202–219PubMedCrossRefGoogle Scholar
  2. 2.
    de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947PubMedGoogle Scholar
  3. 3.
    Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209):1041–1047PubMedCrossRefGoogle Scholar
  4. 4.
    Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229–237PubMedCrossRefGoogle Scholar
  5. 5.
    Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25(12):1539–1544Google Scholar
  6. 6.
    Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A et al (2007) Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 7:91PubMedCrossRefGoogle Scholar
  7. 7.
    Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W et al (2000) Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18(11):2210–2218PubMedGoogle Scholar
  8. 8.
    Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004) Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60(5):1552–1563PubMedGoogle Scholar
  9. 9.
    Jakobs TF, Hoffmann RT, Poepperl G, Schmitz A, Lutz J, Koch W et al (2007) Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol 17(5):1320–1330PubMedCrossRefGoogle Scholar
  10. 10.
    Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE Jr, Loehr SP et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412–425PubMedGoogle Scholar
  11. 11.
    Lewandowski RJ, Thurston KG, Goin JE, Wong CY, Gates VL, Van Buskirk M et al (2005) 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16(12):1641–1651PubMedGoogle Scholar
  12. 12.
    Liu LX, Zhang WH, Jiang HC (2003) Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 9(2):193–200PubMedGoogle Scholar
  13. 13.
    Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D et al (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25(9):1099–1106Google Scholar
  14. 14.
    Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88(2):78–85PubMedCrossRefGoogle Scholar
  15. 15.
    Coldwell DM, Kennedy AS, Nutting CW (2007) Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 69(3):800–804PubMedGoogle Scholar
  16. 16.
    Moroz P, Anderson JE, Van Hazel G, Gray BN (2001) Effect of selective internal radiation therapy and hepatic arterial chemotherapy on normal liver volume and spleen volume. J Surg Oncol 78(4):248–252PubMedCrossRefGoogle Scholar
  17. 17.
    Stubbs RS (2006) Portal hypertension and liver surgery following selective internal radiation therapy with 90Yttrium microspheres. J Clin Oncol 24(9):e15Google Scholar
  18. 18.
    Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68(1):13–23PubMedGoogle Scholar
  19. 19.
    Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z et al (2005) Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16(7):911–935PubMedGoogle Scholar
  20. 20.
    Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. J Vasc Interv Radiol 17(9):1425–1439PubMedGoogle Scholar
  21. 21.
    Salem R, Thurston KG (2006) Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251–1278PubMedCrossRefGoogle Scholar
  22. 22.
    Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J et al (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41(10):1673–1681PubMedGoogle Scholar
  23. 23.
    Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF (2002) Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 13(9 Pt 2):223–229CrossRefGoogle Scholar
  24. 24.
    Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF et al (2005) Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 16(2 Pt 1):205–213PubMedGoogle Scholar
  25. 25.
    Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK (1997) Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 24(3):293–298PubMedGoogle Scholar
  26. 26.
    Ho S, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ et al (1996) Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 23(8):947–952PubMedCrossRefGoogle Scholar
  27. 27.
    Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA, Jr, Kulik L et al (2007) Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 30(4):571–592PubMedCrossRefGoogle Scholar
  28. 28.
    Barnard JA, Marshall GS, Neblett WW, Gray G, Ghishan FK (1986) Noncirrhotic portal fibrosis after Wilms’ tumor therapy. Gastroenterology 90(4):1054–1056PubMedGoogle Scholar
  29. 29.
    Phillips R, Karnofsky DA, Hamilton LD, Nickson JJ (1954) Roentgen therapy of hepatic metastases. Am J Roentgenol Radium Ther Nucl Med 71(5):826–834PubMedGoogle Scholar
  30. 30.
    Wharton JT, Delclos L, Gallager S, Smith JP (1973) Radiation hepatitis induced by abdominal irradiation with the cobalt 60 moving strip technique. Am J Roentgenol Radium Ther Nucl Med 117(1):73–80PubMedGoogle Scholar
  31. 31.
    Clement B, Grimaud JA, Campion JP, Deugnier Y, Guillouzo A (1986) Cell types involved in collagen and fibronectin production in normal and fibrotic human liver. Hepatology 6(2):225–234PubMedCrossRefGoogle Scholar
  32. 32.
    Yokoi Y, Namihisa T, Matsuzaki K, Miyazaki A, Yamaguchi Y (1988) Distribution of Ito cells in experimental hepatic fibrosis. Liver 8(1):48–52PubMedGoogle Scholar
  33. 33.
    Ingold JA, Reed GB, Kaplan HS, Bagshaw MA (1965) Radiation Hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200–208PubMedGoogle Scholar
  34. 34.
    Alati T, Van Cleeff M, Strom SC, Jirtle RL (1988) Radiation sensitivity of adult human parenchymal hepatocytes. Radiat Res 115(1):152–160PubMedCrossRefGoogle Scholar
  35. 35.
    Sempoux C, Horsmans Y, Geubel A, Fraikin J, Van Beers BE, Gigot JF et al (1997) Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology 26(1):128–134PubMedCrossRefGoogle Scholar
  36. 36.
    Lewin K, Millis RR (1973) Human radiation hepatitis. A morphologic study with emphasis on the late changes. Arch Pathol 96(1):21–26PubMedGoogle Scholar
  37. 37.
    Fajardo LF, Colby TV (1980) Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 104(11):584–588PubMedGoogle Scholar
  38. 38.
    Fajardo LF (2005) The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 44(1):13–22PubMedCrossRefGoogle Scholar
  39. 39.
    Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D et al (2005) Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 35(4):222–227PubMedCrossRefGoogle Scholar
  40. 40.
    Stubbs RS, O’Brien I, Correia MM (2006) Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 76(8):696–703PubMedCrossRefGoogle Scholar
  41. 41.
    Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ (2002) Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 29(6):815–820PubMedCrossRefGoogle Scholar
  42. 42.
    Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V et al (2004) Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 45(11):1892–1897PubMedGoogle Scholar
  43. 43.
    Wong CY, Qing F, Savin M, Campbell J, Gates VL, Sherpa KM et al (2005) Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 16(8):1101–1106PubMedGoogle Scholar
  44. 44.
    Wong CY, Savin M, Sherpa KM, Qing F, Campbell J, Gates VL et al (2006) Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma. Cancer Biother Radiopharm 21(4):305–313PubMedCrossRefGoogle Scholar
  45. 45.
    DeLeve LD, Shulman HM, McDonald GB (2002) Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22(1):27–42PubMedCrossRefGoogle Scholar
  46. 46.
    Dulley FL, Kanfer EJ, Appelbaum FR, Amos D, Hill RS, Buckner CD et al (1987) Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 43(6):870–873PubMedGoogle Scholar
  47. 47.
    DeLeve LD, Kaplowitz N (1995) Mechanisms of drug-induced liver disease. Gastroenterol Clin North Am 24(4):787–810PubMedGoogle Scholar
  48. 48.
    Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15(3):460–466PubMedCrossRefGoogle Scholar
  49. 49.
    Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200(6):845–853PubMedCrossRefGoogle Scholar
  50. 50.
    Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065–2072PubMedCrossRefGoogle Scholar
  51. 51.
    Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA (2007) Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11(7):860–868PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • T. F. Jakobs
    • 1
  • S. Saleem
    • 2
  • B. Atassi
    • 2
  • E. Reda
    • 2
  • R. J. Lewandowski
    • 2
  • V. Yaghmai
    • 2
  • F. Miller
    • 2
  • R. K. Ryu
    • 2
  • S. Ibrahim
    • 2
  • K. T. Sato
    • 2
  • L. M. Kulik
    • 2
  • M. F. Mulcahy
    • 2
  • R. Omary
    • 2
  • R. Murthy
    • 3
  • M. F. Reiser
    • 1
  • R. Salem
    • 2
  1. 1.Department of RadiologyLudwig-Maximilians-University of MunichMunichGermany
  2. 2.Department of Interventional RadiologyNorthwestern Memorial HospitalChicagoUSA
  3. 3.Division of Diagnostic ImagingThe University of Texas M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations